IOVA Valuation

Iovance Biotherapeutics Inc

Add to Watchlist

Advanced Chart

2.450

-0.08(-3.162%)1D

Overview
Forecast
Valuation
Earnings

IOVA Relative Valuation

IOVA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IOVA is overvalued; if below, it's undervalued.

Historical Valuation

Iovance Biotherapeutics Inc (IOVA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.82 is considered Undervalued compared with the five-year average of -7.95. The fair price of Iovance Biotherapeutics Inc (IOVA) is between 17.52 to 21.51 according to relative valuation methord. Compared to the current price of 2.50 USD , Iovance Biotherapeutics Inc is Undervalued By 85.7%.

Relative Value

Fair Zone

17.52-21.51

Current Price：2.50

85.7%

Undervalued

-3.15

Trailing

Forward

-2.16

EV/EBITDA

Iovance Biotherapeutics Inc. (IOVA) has a current EV/EBITDA of -2.16. The 5-year average EV/EBITDA is -6.69. The thresholds are as follows: Strongly Undervalued below -16.15, Undervalued between -16.15 and -11.42, Fairly Valued between -1.96 and -11.42, Overvalued between -1.96 and 2.77, and Strongly Overvalued above 2.77. The current Forward EV/EBITDA of -2.16 falls within the Historic Trend Line -Fairly Valued range.

-2.35

EV/EBIT

Iovance Biotherapeutics Inc. (IOVA) has a current EV/EBIT of -2.35. The 5-year average EV/EBIT is -6.50. The thresholds are as follows: Strongly Undervalued below -16.16, Undervalued between -16.16 and -11.33, Fairly Valued between -1.68 and -11.33, Overvalued between -1.68 and 3.15, and Strongly Overvalued above 3.15. The current Forward EV/EBIT of -2.35 falls within the Historic Trend Line -Fairly Valued range.

2.65

Iovance Biotherapeutics Inc. (IOVA) has a current PS of 2.65. The 5-year average PS is 42.75. The thresholds are as follows: Strongly Undervalued below -213.57, Undervalued between -213.57 and -85.41, Fairly Valued between 170.91 and -85.41, Overvalued between 170.91 and 299.08, and Strongly Overvalued above 299.08. The current Forward PS of 2.65 falls within the Historic Trend Line -Fairly Valued range.

-3.62

P/OCF

Iovance Biotherapeutics Inc. (IOVA) has a current P/OCF of -3.62. The 5-year average P/OCF is -10.51. The thresholds are as follows: Strongly Undervalued below -24.49, Undervalued between -24.49 and -17.50, Fairly Valued between -3.53 and -17.50, Overvalued between -3.53 and 3.46, and Strongly Overvalued above 3.46. The current Forward P/OCF of -3.62 falls within the Historic Trend Line -Fairly Valued range.

-4.18

P/FCF

Iovance Biotherapeutics Inc. (IOVA) has a current P/FCF of -4.18. The 5-year average P/FCF is -9.82. The thresholds are as follows: Strongly Undervalued below -22.24, Undervalued between -22.24 and -16.03, Fairly Valued between -3.60 and -16.03, Overvalued between -3.60 and 2.61, and Strongly Overvalued above 2.61. The current Forward P/FCF of -4.18 falls within the Historic Trend Line -Fairly Valued range.

Iovance Biotherapeutics Inc (IOVA) has a current Price-to-Book (P/B) ratio of 1.32. Compared to its 3-year average P/B ratio of 2.90 , the current P/B ratio is approximately -54.67% higher. Relative to its 5-year average P/B ratio of 4.05, the current P/B ratio is about -67.45% higher. Iovance Biotherapeutics Inc (IOVA) has a Forward Free Cash Flow (FCF) yield of approximately -33.24%. Compared to its 3-year average FCF yield of -23.36%, the current FCF yield is approximately 42.28% lower. Relative to its 5-year average FCF yield of -17.40% , the current FCF yield is about 91.06% lower.

1.20

P/B

Median3y

2.90

Median5y

4.05

-35.34

FCF Yield

Median3y

-23.36

Median5y

-17.40

Competitors Valuation Multiple

The average P/S ratio for IOVA's competitors is 77.99, providing a benchmark for relative valuation. Iovance Biotherapeutics Inc Corp (IOVA) exhibits a P/S ratio of 2.65, which is -96.60% above the industry average. Given its robust revenue growth of 92.73%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

IOVA.O

Iovance Biotherapeutics Inc

Mineralys Therapeutics Inc

Performance Decomposition

Market capitalization of IOVA decreased by 78.99% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 31.11M to 59.95M.

The secondary factor is the Margin Expansion, contributed -40.34%to the performance.

Overall, the performance of IOVA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

92.73%

31.11M → 59.95M

Revenue Growth

-40.34%

-312.16 → -186.25

Margin Expansion

-131.38%

6.35 → -1.99

P/E Change

-78.99%